A foremost law firm in mesothelioma Goldberg, Persky and White, P.C proudly announces its readiness to fight for mesothelioma and asbes...
Read More
Showing posts with label mesothelioma. Show all posts
Showing posts with label mesothelioma. Show all posts
Mesothelioma Victims Center Now Urges Any Diagnosed Navy Veterans Whose Exposure to Asbestos Happened at Norfolk Virginia to Call About the Nation's Top Compensation Lawyers
NEW YORK , July 6, 2017 /PRNewswire/ -- According to the Mesothelioma Victims Center , "We are extremely passionate when it comes...
Read More
Mesothelioma Compensation Center Now Offers a Water District Maintenance Worker with Mesothelioma Instant Access to the Nation's Most Skilled Lawyers for Better Compensation Results
NEW YORK , July 12, 2017 /PRNewswire/ -- The Mesothelioma Compensation Center says, "We understand water districts as well as almo...
Read More
Mesothelioma Victims Center Now Urges a Veteran With Mesothelioma Due to Asbestos Exposure at a Navy Shipyard to Call for Direct Access to the Nation's Top Compensation Results Attorneys
NEW YORK , July 27, 2017 /PRNewswire/ -- The Mesothelioma Victims Center says, "What we've found over the years is nearly 50% ...
Read More
How to Improve a Mesothelioma Prognosis
Mesothelioma is a rare form of cancer which can take decades for outward symptoms to appear. Because of this, the prognosis for many mes...
Read More
Bayer’s Drug Failed to Improve Mesothelioma Survival
Drug manufacturers announced disappointing ends recently to two different clinical trials involving pleural mesothelioma, dampening e...
Read More
Mesothelioma Compensation Center Appeals to a Nuclear Navy or Power Plant Worker with Mesothelioma to Call Them for On-The-Spot Access to the Nation's Top Compensation Lawyers
NEW YORK , July 26, 2017 /PRNewswire/ -- According to the Mesothelioma Compensation Center, "We are the top-rated group in the natio...
Read More
AstraZeneca’s Mesothelioma Therapy Tremelimumab Disappoints in Phase 2b Clinical Trial
A Phase 2b clinical trial of AstraZeneca’s mesothelioma therapy tremelimumab showed no significant difference in survival times between t...
Read More
Subscribe to:
Posts (Atom)